Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014
| Autor: | Elizabeth R. Unger, Elissa Meites, Martin Steinau, Lauri E. Markowitz, Julia W. Gargano, Eileen M. Dunne, Gui Liu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Adolescent Sexual Behavior Sexually Transmitted Diseases Herd immunity 03 medical and health sciences Young Adult 0302 clinical medicine Risk Factors Epidemiology medicine Prevalence Immunology and Allergy Humans Sex organ 030212 general & internal medicine Papillomavirus Vaccines Human papillomavirus Papillomaviridae National health Hpv types business.industry Papillomavirus Infections Vaccination Middle Aged Nutrition Surveys Confidence interval United States Editorial Commentary 030104 developmental biology Infectious Diseases Sexual Partners DNA Viral Female business Demography |
| Zdroj: | The Journal of infectious diseases. 215(7) |
| ISSN: | 1537-6613 |
| Popis: | Background We report the first nationally representative prevalence data on genital human papillomavirus (HPV) in males in the United States, using findings from the National Health and Nutrition Examination Surveys, 2013-2014. Methods Using penile swabs from males aged 14-59 years, we estimated the HPV DNA prevalence and prevalence ratios (PRs) with respect to sexual behaviors and demographic characteristics. Results The prevalence of any HPV was 42.2% (95% confidence interval [CI], 38.3%-46.1%) and of high-risk (HR) HPV was 23.4% (95% CI, 21.3%-25.6%). Prevalence of any HPV was 12.5% in 14-19 year olds and was higher in older age groups, through ages 25-29 years, and then similar through age 59 years. After adjustment for age and race, any HPV prevalence was associated with lifetime number of sex partners (≥15 vs 1-2; PR, 3.27; 95% CI, 2.12-5.02) and past-year number of sex partners (≥2 vs 0; PR, 1.26; 95% CI, 1.09-1.46). Comparisons of consecutively older age groups revealed that the prevalence of quadrivalent HPV vaccine types (4vHPV), types 6, 11, 16, and 18, was significantly higher only between ages 25-29 and 20-24 years (PR, 2.79; 95% CI, 1.31-5.96), whereas the prevalence of other HPV types was significantly higher only between ages 20-24 and 14-19 years (PR, 3.39; 95% CI, 2.49-4.61). Conclusions Overall, 42.2% of US males aged 14-59 years have detectable genital HPV infections. Differences in the age-specific prevalence of 4vHPV types and non-4vHPV types suggest that the vaccination program has had an impact on the prevalence of HPV types 6, 11, 16, and 18 among males. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|